Phathom Pharmaceuticals Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Die Gewinne von Phathom Pharmaceuticals sind mit einer durchschnittlichen Jahresrate von -9.5% zurückgegangen, während die Gewinne der Branche Pharmaceuticals um 12.6% pro Jahr wuchsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Jahresrate von 83.4%.
Wichtige Informationen
-9.48%
Wachstumsrate der Gewinne
6.39%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 5.95% |
| Wachstumsrate der Einnahmen | 83.42% |
| Eigenkapitalrendite | n/a |
| Netto-Marge | -41.34% |
| Letzte Ertragsaktualisierung | 30 Jun 2026 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Narrative-Update • Sep 09
PHAT: Label Expansion Plans And 2026 Profitability Path Will Support Bullish Repricing
Analysts have reset the fair value estimate for Phathom Pharmaceuticals to $10, reflecting a lower price target that they link to reduced revenue growth and profit margin expectations, a slightly higher discount rate, and more cautious assumptions around Voquezna uptake in a highly genericized market. Analyst Commentary Recent Street research on Phathom Pharmaceuticals points to a more cautious tone around Voquezna and the company’s execution against its growth plans.Seeking Alpha • Sep 09
Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case
Summary Phathom Pharmaceuticals is executing a specialist-focused strategy, targeting gastroenterologists to drive VOQUEZNA adoption and move toward sustainable profitability. Second-quarter 2026 revenue grew 88% to $74.3M, SG&A fell, and management forecasts 2026 revenue of $310–$325M with an 80% gross margin, signaling operating leverage. PHAT’s commercial runway is supported by $182.5M in cash and improved operating cash flows, but revenue-interest financing remains a material risk. Key value drivers include continued growth in covered prescriptions, disciplined spending, and successful as-needed dosing development, with competition from tegoprazan looming. Read the full article on Seeking Alpha
Narrative-Update • Aug 15
PHAT: Expanded Reflux Indication Will Support Anticipated 2026 Profitability Timeline
Analysts have trimmed the fair value estimate for Phathom Pharmaceuticals from $23.70 to $21.50 as recent cuts to Street price targets, slightly higher discount assumptions, and more cautious revenue growth and margin forecasts feed into updated models. Analyst Commentary Recent Street research on Phathom Pharmaceuticals points to a more cautious stance on valuation, even as several analysts keep positive ratings on the stock.Narrative-Update • Jun 15
PHAT: Research Momentum And 2026 Profitability Outlook Will Support Bullish Repricing
Analysts have raised their price target on Phathom Pharmaceuticals to $13.62, reflecting updated assumptions for the discount rate, revenue growth, profit margin, and future P/E following recent research support. What's in the News Phathom highlighted extensive clinical and scientific research on vonoprazan, the active ingredient in VOQUEZNA, at Digestive Disease Week 2026 in Chicago.Narrative-Update • Jun 01
PHAT: Clinical Momentum Will Support Anticipated 2026 Profitability Timeline
Analysts have adjusted their price target on Phathom Pharmaceuticals to $23.70. This reflects updated views on the discount rate, long-term margin potential, and future P/E assumptions following recent research commentary.Narrative-Update • May 02
PHAT: Regulatory Exclusivity Outlook Will Support Anticipated 2026 Profitability Timeline
Narrative update on Phathom Pharmaceuticals The updated analyst price target for Phathom Pharmaceuticals has moved to $23.70, with analysts pointing to refreshed models that factor in revised revenue growth and profit margin assumptions, an adjusted future P/E, and recent research highlighting expectations around potential profitability timing, regulatory exclusivity and consumer marketing uncertainty. Analyst Commentary Recent Street research on Phathom Pharmaceuticals highlights a mix of optimism around the path to profitability and caution around long term exclusivity and commercial execution.Narrative-Update • Apr 15
PHAT: Regulatory Exclusivity Outlook Supports Path To 2026 Profitability
Phathom Pharmaceuticals' fair value estimate has shifted from $22.90 to $23.70 as analysts factor in higher long term profit margin assumptions, recent price target increases to $25 and $13, and updated views on regulatory exclusivity and potential generic competition after 2032. Analyst Commentary Recent Street research provides a mixed but useful view of how expectations are settling around Phathom Pharmaceuticals' execution and long term earnings power.Narrative-Update • Apr 01
PHAT: Profitability In 2026 Will Challenge Post 2032 Generic Overhang
Narrative Update The analyst price target for Phathom Pharmaceuticals is now aligned with a fair value estimate of about $13.62, with analysts pointing to updated models following Q4 results, refined assumptions around revenue growth, profit margins and future P/E, as well as recent target increases to $13 and $25 that reflect views on regulatory exclusivity and the path toward potential profitability in early Q3 2026. Analyst Commentary Recent Street research around Phathom Pharmaceuticals has centered on updated models following Q4 results, with analysts adjusting their targets to reflect revised assumptions on regulatory exclusivity, marketing execution and the timing of potential profitability.Narrative-Update • Mar 18
PHAT: Profitability In 2026 Will Test Post 2032 Generic Assumptions
Narrative Update on Phathom Pharmaceuticals Analysts have raised Phathom Pharmaceuticals' price target to a range that now reaches up to $25, up from prior targets as low as $12, citing updated models after the Q4 earnings beat, revised assumptions around regulatory exclusivity and generic entry after 2032, and expectations for the company to work toward profitability in early Q3 2026. Analyst Commentary Analysts reviewing Phathom Pharmaceuticals after its Q4 earnings beat have adjusted their models and price targets, but with differing levels of enthusiasm.Narrative-Update • Mar 04
PHAT: Profitability Expected In 2026 Could Reframe Long Term Generic Risk
Narrative Update on Phathom Pharmaceuticals The analyst price target underpinning our fair value view on Phathom Pharmaceuticals has shifted from $12 to $13. This reflects updated models that factor in the recent Q4 earnings beat, revised assumptions on regulatory exclusivity and potential generic entry after 2032, and expectations around the company's path toward potential profitability in early Q3 2026.Narrative-Update • Feb 18
PHAT: Follow On Equity Raise Will Support Path To 2026 Profitability
Analysts have kept their $22.90 price target for Phathom Pharmaceuticals broadly unchanged, citing only marginal adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions in their valuation work. What's in the News Phathom Pharmaceuticals completed a follow on equity offering totaling approximately US$130.0 million.Narrative-Update • Feb 04
PHAT: Equity Raise And 2026 Profitability Outlook Will Support Further Upside
Analysts have maintained their overall view on Phathom Pharmaceuticals, making only modest adjustments to assumptions such as revenue growth, profit margin, and future P/E. Taken together, these inputs support an unchanged fair value estimate of US$22.90 per share.Narrative-Update • Jan 20
PHAT: Equity Raise And 2025 Profitability Outlook Will Support Further Upside
Analysts have modestly adjusted their price assumptions for Phathom Pharmaceuticals, and the implied fair value remains at $22.90. Small changes to revenue growth, profit margin expectations, and future P/E assumptions have effectively offset one another.Analyseartikel • Jan 08
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27%
Despite an already strong run, Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shares have been powering on, with a gain...Narrative-Update • Jan 06
PHAT: Late-Stage Gastrointestinal Trials And 2025 Guidance Will Drive Upside Momentum
Analysts have maintained their price target for Phathom Pharmaceuticals at US$22.90. This reflects only minor adjustments in key model inputs, including the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any change in their overall view.Narrative-Update • Dec 16
PHAT: Late-Stage Gastrointestinal Pipeline Progress Will Drive Upside Momentum
Analysts have slightly trimmed their price target on Phathom Pharmaceuticals from approximately $23.13 to $22.90 per share, reflecting modestly higher long term growth and margin expectations, offset by a lower projected valuation multiple. What's in the News First patient dosed in the Phase 2 pHalcon EoE-201 trial of VOQUEZNA tablets for eosinophilic esophagitis in adults, with topline results expected in 2027 (company announcement) Additional analyses from the pivotal Phase 3 pHalcon NERD-301 trial of VOQUEZNA in Non Erosive Reflux Disease published in the American Journal of Gastroenterology, highlighting benefits for nighttime GERD symptoms (company announcement, medical journal) Full year 2025 revenue guidance updated to a range of 170 million dollars to 175 million dollars, indicating expectations for continued commercial ramp (company guidance) Sanjeev Narula appointed Chief Financial and Business Officer, bringing extensive large cap pharma and transaction experience from prior CFO roles at Intra Cellular Therapies, Viatris, and Pfizer divisions (company announcement) Valuation Changes Fair Value Estimate has edged down slightly from approximately $23.13 to $22.90 per share.Narrative-Update • Dec 01
PHAT: Clinical Pipeline Advances And Index Inclusion Will Support Upside Momentum
Analysts have maintained their price target for Phathom Pharmaceuticals at $23.13 per share, citing consistent revenue growth expectations and stable profit margin forecasts as the basis for leaving their projections unchanged. What's in the News First patient dosed in Phase 2 pHalcon-EoE-201 clinical trial of VOQUEZNA tablets for eosinophilic esophagitis in adults, with primary and secondary results expected in 2027 (Key Developments) Updated full-year 2025 revenue guidance to a range of $170 million to $175 million (Key Developments) New data from Phase 3 pHalcon-NERD-301 trial for VOQUEZNA published, showing improvements in nocturnal symptoms for Non-Erosive Reflux Disease and highlighting safety considerations (Key Developments) Appointment of Sanjeev Narula as Chief Financial and Business Officer, bringing extensive financial and strategic experience from leadership roles at Intra-Cellular Therapies, Viatris, and Pfizer (Key Developments) Added to S&P Pharmaceuticals Select Industry Index (Key Developments) Valuation Changes Consensus Analyst Price Target remains steady at $23.13 per share with no change from previous estimates.Narrative-Update • Nov 17
PHAT: Early Clinical Trial Progress Will Drive Shares Higher
Analysts have maintained their fair value price target for Phathom Pharmaceuticals at $23.13 per share. They cite only marginal adjustments to growth estimates and risk assumptions.Narrative-Update • Nov 01
PHAT: Rising Profit Margins Will Drive Stronger Shareholder Value Ahead
Analysts have raised their price target for Phathom Pharmaceuticals from $21.38 to $23.13. They cite an improved profit margin outlook, despite more conservative revenue growth projections.Narrative-Update • Sep 04
Gastroenterology Focus Will Unlock Enduring Market Potential
Analysts reaffirmed their price target for Phathom Pharmaceuticals at $21.38, citing 10-year market exclusivity for Voquezna, diminished generic risk, and robust launch metrics as drivers of renewed confidence and market opportunity. Analyst Commentary FDA granted 10-year market exclusivity for Voquezna tablets under GAIN, extending exclusivity to May 2032 with a likely pediatric extension through late 2032.Analyseartikel • Jul 19
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge
Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shares have retraced a considerable 27% in the last month, reversing a...Analyseartikel • Jun 02
Investors Still Aren't Entirely Convinced By Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Revenues Despite 54% Price Jump
Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shareholders are no doubt pleased to see that the share price has bounced...Neues Narrative • May 09
Focused VOQUEZNA Marketing And Cost Cuts Will Secure 2032 Exclusivity
Phathom focuses on VOQUEZNA's market potential in GERD treatment to drive substantial revenue while aiming for profitability through strategic cost management.Analyseartikel • Apr 18
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge
Unfortunately for some shareholders, the Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) share price has dived 27% in the...Seeking Alpha • Dec 11
Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable
Summary Phathom Pharmaceuticals, Inc.'s vonoprazan received multiple approvals, but the stock price showed erratic behavior, spiking post-Q2 earnings and plummeting post-Q3 earnings. Despite significant prescription growth and revenue increases, Q3 showed slower progress, raising concerns about the drug's market uptake and second-line approval status. High SG&A expenses and limited cash runway pose financial risks, alongside unclear reasons for stagnant sales despite label expansions. I exited my PHAT position in August and have no plans to reinvest due to these uncertainties and financial concerns. Read the full article on Seeking AlphaSeeking Alpha • Sep 03
Following Up On Phathom Pharmaceuticals
Summary Today, we're following up on Phathom Pharmaceuticals to see how the marketing rollout of its flagship product VOQUENZA is proceeding. This drug received FDA clearance late last year and is aiming to displace Proton Pump Inhibitors in its market. Management has succeeded in getting the compound covered in most commercial plans and believes VOQUENZA have at least $3 billion in peak sales potential. However, the company is still seeing a significant quarterly cash burn rate and already has a decent chunk of debt on its balance sheet. Read the full article on Seeking AlphaSeeking Alpha • Jun 26
Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
Summary Phathom Pharmaceuticals stock has significantly declined since 2021, despite securing FDA approval for Vonoprazan to treat H. pylori infection and GERD. The company faced delays in launching its products due to the presence of a cancer-causing agent in commercial batches, but eventually received full FDA approval. PHAT aims to target a substantial market opportunity with Vonoprazan, potentially leading to a share price rally and challenging a billion-dollar market cap valuation. The delays in launching Voquenza have been frustrating, but now the company is conducting a full launch and may secure a lucrative label expansion with an approval in non-erosive GERD next month. Read the full article on Seeking AlphaAufschlüsselung der Einnahmen und Ausgaben
Aufschlüsselung der Einnahmen und Ausgaben
Wie Phathom Pharmaceuticals Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 26 | 240 | -99 | 209 | 30 |
| 31 Mar 26 | 205 | -157 | 239 | 31 |
| 31 Dec 25 | 175 | -221 | 280 | 33 |
| 30 Sep 25 | 147 | -275 | 308 | 34 |
| 30 Jun 25 | 114 | -330 | 333 | 36 |
| 31 Mar 25 | 82 | -346 | 323 | 34 |
| 31 Dec 24 | 55 | -334 | 291 | 34 |
| 30 Sep 24 | 26 | -339 | 271 | 39 |
| 30 Jun 24 | 10 | -297 | 218 | 42 |
| 31 Mar 24 | 3 | -247 | 161 | 48 |
| 31 Dec 23 | 1 | -202 | 118 | 50 |
| 30 Sep 23 | 0 | -177 | 92 | 52 |
| 30 Jun 23 | 0 | -185 | 92 | 59 |
| 31 Mar 23 | 0 | -195 | 99 | 65 |
| 31 Dec 22 | 0 | -198 | 101 | 71 |
| 30 Sep 22 | 0 | -179 | 90 | 69 |
| 30 Jun 22 | 0 | -164 | 83 | 67 |
| 31 Mar 22 | 0 | -150 | 70 | 69 |
| 31 Dec 21 | 0 | -144 | 63 | 72 |
| 30 Sep 21 | 0 | -162 | 54 | 100 |
| 30 Jun 21 | 0 | -159 | 45 | 110 |
| 31 Mar 21 | 0 | -144 | 36 | 103 |
| 31 Dec 20 | 0 | -129 | 28 | 98 |
| 30 Sep 20 | 0 | -173 | 20 | 69 |
| 30 Jun 20 | 0 | -207 | 14 | 48 |
| 31 Mar 20 | 0 | -274 | 11 | 36 |
| 31 Dec 19 | 0 | -255 | 7 | 20 |
| 30 Sep 19 | 0 | -158 | 4 | 8 |
| 30 Jun 19 | 0 | -90 | 3 | 3 |
| 31 Mar 19 | 0 | -2 | 2 | 0 |
Qualität der Erträge: PHAT ist derzeit unrentabel.
Wachsende Gewinnspanne: PHAT ist derzeit unrentabel.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: PHAT ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 9.5% pro Jahr zugenommen.
Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von PHAT verglichen werden, da das Unternehmen derzeit nicht profitabel ist.
Erträge im Vergleich zur Industrie: PHAT ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Pharmaceuticals (1%) erschwert.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: PHATDie Verbindlichkeiten des Unternehmens übersteigen seine Vermögenswerte, so dass es schwierig ist, seine Eigenkapitalrendite zu berechnen.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/11 06:57 |
| Aktienkurs zum Tagesende | 2026/09/11 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Phathom Pharmaceuticals, Inc. wird von 16 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jenna Davidner | Barclays |
| null null | BMO Capital Markets Equity Research |
| Kristen Kluska | Cantor Fitzgerald & Co. |